NextCell's biobank Cellaviva has received permission from IVO to handle stem cells from adipose tissue
NextCell Pharma AB ("NextCell") announces today that its biobank Cellaviva has been granted an extended permit from the Health and Care Inspectorate (IVO), to also handle and store stem cells from adipose tissue. The decision enables the company to launch its new service, stem cell saving for adults.
The company has previously been authorized by IVO to operate a tissue establishment using cells from the umbilical-cord and umbilical-cord-blood from newborns and operates a biobank for family saving of these cells. The extended approval state of fat-derived stem cells means for the fat-derived stem cells means that the company now also may offer adults the opportunity to store their stem cells. The cells are collected through liposuction, purified and processed and then frozen in liquid nitrogen and stored for possible future use. Adipose tissue is a specialized connective tissue which contains connective tissue formation or mesenchymal stem cells similar to umbilical cord tissue.
“The Permit from IVO enables us to offer stem cell saving for adults,” says Mathias Svahn, CEO of NextCell.
This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 5th of April 2019.
Stay up to date with the latest development in NextCell Pharma
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com
About NextCell Pharma AB:
Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.